^18PDG PET/CT评价利妥昔单抗联合CHOP方案治疗9例弥漫大B细胞淋巴瘤的疗效

目的：探讨18F标记的2-脱氧葡萄糖正电子发射断层显像技术（^18PDG PET／CT）在接受R-CHOP方案（利妥昔单抗＋环磷酰胺、阿霉素、长春新碱和强的松）治疗的弥漫大B细胞淋巴瘤（DLBCL）患者疗效评价中的价值。方法：回顾了我院2005．5-2007．5月收治的9例接受了R-CHOP方案治疗且接受了PET／CT评价的DLBCL患者的临床资料，分析PET／CT对这9例患者在治疗过程中的疗效评价情况，以及对治疗的指导价值。结论：PET／CTLL常规方法更有能准确、有效地对DLBCL患者的治疗效果进行评价，对DLBCL进一步治疗的决策及患者的预后判断有重要的价值。

18PDG PET/CT in Evaluating the Therapeutic Response of 9 Patients with Diffuse Large B Cell Lymphoma Treated with Rituximab Combined with CHOP Regimen

Objective： To investigate the clinical value of 18F fluorodeoxyglucose （FDG） PET in evaluating the therapeutic response of patients with diffuse large B cell lymphoma（DLBCL） treated with R-CHOP regimen （Rituximab combined with cyclophosphamide, adriamyein,vincr-stine and prednisone）. Methods We had reviewed the clinicai documents of 9 patients diagnosed as DLBCL and treated in our hospital between 2005.5 and 2007.5, receiving R-CHOP regimen and PET/CT evaluation., and made a analysis of PET/CT in evaluating the therapeutic response of these 9 patients in the process of treatment, and its value of guiding further treatment. Conclusion： PET/CT is able to evaluate patients＇ response to treatment more accurately and effectively than traditional methods, and of great significance in making further treatment strategies and predicting prognosis for patients with DLBCL.